Further evidence for PHF6 mutations acquired secondarily and leading to progression of myeloid neoplasms was found in patients with germline mutations of RUNX1, where PHF6 mutations were implicated in the transition to MDS in one patient and the transition to AML in the other (56, 57). This evidence concerns the gene PHF6 and acute myeloid leukemia.